{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T12:52:51Z","timestamp":1765975971719},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.clinthera.2012.12.011","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T06:47:10Z","timestamp":1358318830000},"page":"180-189","source":"Crossref","is-referenced-by-count":45,"title":["Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"35","author":[{"given":"Peng","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lulu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.12.011_bib1","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.12.011_bib2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3810\/psm.2011.11.1946","article-title":"2011 recommendations for the diagnosis and management of gout and hyperuricemia","volume":"39","author":"Hamburger","year":"2011","journal-title":"Phys Sportsmed"},{"key":"10.1016\/j.clinthera.2012.12.011_bib3","first-page":"215","article-title":"Hyperuricemia and gout: new insights into pathogenesis and treatment","volume":"65","author":"Pillinger","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.clinthera.2012.12.011_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2146\/ajhp100394","article-title":"Febuxostat for treatment of chronic gout","volume":"68","author":"Gray","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.clinthera.2012.12.011_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2012.12.011_bib6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.amjmed.2005.03.043","article-title":"Serum uric acid and cardiovascular disease: recent developments, and where do they leave us?","volume":"118","author":"Baker","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2012.12.011_bib7","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","article-title":"Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992","volume":"283","author":"Fang","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2012.12.011_bib8","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/art.23121","article-title":"Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study","volume":"58","author":"Ioachimescu","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.12.011_bib9","first-page":"577","article-title":"Treatment of chronic gout","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2012.12.011_bib10","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23007","article-title":"Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout?","volume":"57","author":"Perez-Ruiz","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.12.011_bib11","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2012.12.011_bib12","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.12.011_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/01.rhu.0000209882.50228.9f","article-title":"Serum urate levels and gout flares: analysis from managed care data","volume":"12","author":"Sarawate","year":"2006","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2012.12.011_bib14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.12.011_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1525-139X.2007.00270.x","article-title":"Allopurinol dosing in renal impairment: walking the tightrope between adequate urate lowering and adverse events","volume":"20","author":"Dalbeth","year":"2007","journal-title":"Semin Dial"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2012.12.011_bib16","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/ar1909","article-title":"Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics","volume":"8","author":"Terkeltaub","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2012.12.011_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0002-9343(68)90008-9","article-title":"Renal clearance of oxipurinol, the chief metabolite of allopurinol","volume":"45","author":"Elion","year":"1968","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2012.12.011_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/106002809302700317","article-title":"Allopurinol hypersensitivity syndrome: a review","volume":"27","author":"Arellano","year":"1993","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2012.12.011_bib19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity","volume":"76","author":"Hande","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2012.12.011_bib20","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.lfs.2004.10.031","article-title":"Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase\/xanthine dehydrogenase","volume":"76","author":"Takano","year":"2005","journal-title":"Life Sci"},{"key":"10.1016\/j.clinthera.2012.12.011_bib21","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1002\/art.24209","article-title":"Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial","volume":"59","author":"Schumacher","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.12.011_bib23","author":"Higgins"},{"key":"10.1016\/j.clinthera.2012.12.011_bib24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"10.1016\/j.clinthera.2012.12.011_bib25","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2012.12.011_bib26","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/art.20935","article-title":"Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout","volume":"52","author":"Becker","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2012.12.011_bib27","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2012.12.011_bib28","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.080814","article-title":"Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2012.12.011_bib29","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"4 Suppl 2","key":"10.1016\/j.clinthera.2012.12.011_bib30","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1097\/RHU.0b013e31821d352f","volume":"17","author":"Naoyuki","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2012.12.011_bib31","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/RHU.0b013e31821d36cc","volume":"17","author":"Kamatani","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2012.12.011_bib32","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1097\/RHU.0b013e31821d351d","article-title":"Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study","volume":"17","author":"Naoyuki","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2012.12.011_bib33","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/RHU.0b013e31821d36de","article-title":"Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study","volume":"17","author":"Naoyuki","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2012.12.011_bib34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/acr.20680","article-title":"Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol","volume":"64","author":"Chohan","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.clinthera.2012.12.011_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00045391-200501000-00005","article-title":"Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment","volume":"12","author":"Mayer","year":"2005","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2012.12.011_bib36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4065\/81.7.925","article-title":"Gout medication treatment patterns and adherence to standards of care from a managed care perspective","volume":"81","author":"Sarawate","year":"2006","journal-title":"Mayo Clin Proc"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812007230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812007230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T09:52:33Z","timestamp":1539942753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812007230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0149291812007230"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.12.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}